KnowMyeloma Day is an annual awareness day held on the last Thursday of September (September 24, 2026) during Blood Cancer Awareness month. The purpose of this day is to educate the public about multiple myeloma, an incurable (but very treatable) blood cancer. It’s an opportunity to invite patients, caregivers, doctors, and advocates to share personal stories, helpful resources, or facts of life with this disease.
Multiple Myeloma is a type of blood cancer that develops in the plasma cells, which are white blood cells that fight infection and are located in your bone marrow. These plasma cells multiply uncontrollably, crowding out healthy blood cells and producing abnormal proteins called M-proteins. While there is currently no cure, advancements in therapy have significantly improved the prognosis and quality of life for patients.
Here is the latest myeloma news on HealthTree:
Inobrodib: A New Oral Myeloma Treatment With Dr. Nisha Joseph (Podcast Episode)
A new oral myeloma treatment is now in development. It doesn’t work like anything else in your treatment history and has activity in patients who have run out of options. Listen as Dr. Nisha Joseph of Emory’s Winship Cancer Institute breaks down how Inobrodib works, who it might help, and where it fits in the future of myeloma care.
Multiple Myeloma In Young Adults: Brice Davis’ Story
Brice Davis was diagnosed with multiple myeloma in his early thirties. Today, he is sharing his story with HealthTree to highlight that blood cancers can affect people at many different stages of life. He hopes to raise awareness of myeloma and encourage others facing a diagnosis to keep moving forward.
A New Genomic Definition of High-Risk Myeloma, Validated in Thousands of Patients
A large French analysis presented at the 2026 COMy (Controversies in Multiple Myeloma) Conference has confirmed that a new international consensus for identifying high-risk multiple myeloma works as intended, and that around 30% of newly diagnosed patients fall into the high-risk category at diagnosis.
Treatments for multiple myeloma have improved enormously over the past two decades. Projected progression-free survival (the time before the disease worsens) now reaches 17 years for transplant-eligible patients and 8 years for senior non-transplant patients. Even so, some patients still relapse early, and identifying them at diagnosis would allow doctors to match treatment intensity to risk.
To address this gap, the IMS/IMWG Consensus Genomic Staging (CGS) for high-risk myeloma was developed at a workshop in Barcelona in 2023. Dr. Jill Corre presented her group’s validation of this consensus in thousands of French patients.
FDA Approves Iberdomide (Zenbexus) With Daratumumab and Dexamethasone for Multiple Myeloma
On August 31, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to iberdomide (Zenbexus) combined with daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This new combination is called IberDd. This is the first approval for a new class of medication called cereblon E3 ligase modulator (CELMoD).
Study Shows Two Years of Maintenance Therapy May Be Enough For Some People With Multiple Myeloma
For many people with multiple myeloma, maintenance therapy becomes part of everyday life. After initial treatment, many patients continue taking lenalidomide (Revlimid) to help keep multiple myeloma under control. Currently, the standard of care is to continue maintenance therapy until myeloma gets worse.
Now researchers are trying to learn how long patients need maintenance therapy. New results for the Phase 3 ENDURANCE trial show that, for patients who did not receive an autologous stem cell transplant, continuing lenalidomide for a long period of time may not be necessary for better survival outcomes. In fact, researchers also found that longer treatment was linked to more side effects and a higher risk of developing second cancers.
Take Control of Your Multiple Myeloma Care: Expert Guidance on Treatment, Advocacy, and Second Opinions (Event Recording)
Shaping a personalized care plan for multiple myeloma begins with understanding your options, discovering helpful resources, and finding your voice. Join us for an empowering webinar featuring Dr. Shonali Midha from the Dana-Farber Cancer Institute as she shares expert guidance on how patients and caregivers can approach their care plans with clarity and build a medical team they trust.
During this session, Dr. Midha will discuss the critical importance of seeking a second opinion in multiple myeloma care and how doing so can open doors to emerging therapies. You will also learn actionable strategies to effectively advocate for yourself, navigate complex treatment decisions with confidence, and uncover valuable resources designed to support you and your family.
Conclusion
KnowMyeloma Day 2026 is an important reminder of how far multiple myeloma care has come and how much work remains to be done. From new treatments to advances in identifying high-risk disease, ongoing research continues to create new possibilities for patients.
At HealthTree we share patient stories, expert guidance, advocacy, and access to trusted information to help people feel more informed and empowered through their myeloma journey. On this KnowMyeloma Day, we invite the myeloma community to share knowledge, support one another, and continue pushing toward a future where every person affected by multiple myeloma has more effective treatment options and, ultimately, a cure.
Keep track of your health with HealthTree
Navigating a multiple myeloma diagnosis is easier when you have access to personalized tools, trustworthy education, and a supportive community. The HealthTree Foundation offers free resources to empower patients and caregivers at every step:
